Role of β-blockers in the cardiovascular disease continuum: a collaborative Delphi survey-based consensus from Asia-Pacific

References

• Ziff OJ, Samra M, Howard JP, et al. Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. BMC Med. 2020;18(1):103. doi: 10.1186/s12916-020-01564-3.
   PubMed Web of Science ®Google Scholar
• Koracevic G, Micic S, Stojanovic M, et al. Compelling indications should be listed for individual beta-blockers (due to diversity), not for the whole class. Curr Vasc Pharmacol. 2021;19(4):343–346. doi: 10.2174/1570161118666200518113833.
   PubMed Web of Science ®Google Scholar
• Wiysonge CS, Bradley HA, Volmink J, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2012;11: Cd002003.
   PubMedGoogle Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021–3104. doi: 10.1093/eurheartj/ehy339.
   PubMed Web of Science ®Google Scholar
• Whelton P, Carey R, Aronow W, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood ppressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13–e115. doi: 10.1161/HYP.0000000000000065.
   PubMed Web of Science ®Google Scholar
• Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334–1357. doi: 10.1161/HYPERTENSIONAHA.120.15026.
   PubMed Web of Science ®Google Scholar
• Kaul U, Bhagwat A, Omboni S, et al. Blood pressure and heart rate related to sex in untreated subjects: the India ABPM study. J Clin Hypertens (Greenwich). 2020;22(7):1154–1162. doi: 10.1111/jch.13894.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan S, Zachariah G, Gupta K, et al. Prevalence of hypertension among indian adults: results from the great India blood pressure survey. Indian Heart J. 2019;71(4):309–313. doi: 10.1016/j.ihj.2019.09.012.
   PubMedGoogle Scholar
• Floras JS, Hara K. Sympathoneural and haemodynamic characteristics of young subjects with mild essential hypertension. J Hypertens. 1993;11(6):647–655. doi: 10.1097/00004872-199306000-00009.
   PubMed Web of Science ®Google Scholar
• Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006;174(12):1737–1742. doi: 10.1503/cmaj.060110.
   PubMed Web of Science ®Google Scholar
• Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338(may19 1):b1665–b1665. doi: 10.1136/bmj.b1665.
   PubMed Web of Science ®Google Scholar
• Xing F, Chen J, Zhao B, et al. Real role of β-blockers in regression of left ventricular mass in hypertension patients: Bayesian network meta-analysis. Medicine (Baltimore). 2017;96(10):e6290. doi: 10.1097/MD.0000000000006290.
   PubMed Web of Science ®Google Scholar
• Muresan L, Cismaru G, Muresan C, et al. Beta-blockers for the treatment of arrhythmias: bisoprolol – a systematic review. Ann Pharm Fr. 2022;80(5):617–634. doi: 10.1016/j.pharma.2022.01.007.
   PubMed Web of Science ®Google Scholar
• Bühler FR, Berglund G, Anderson OK, et al. Double-blind comparison of the cardioselective beta-blockers bisoprolol and atenolol in hypertension: the bisoprolol international multicenter study (BIMS). J Cardiovasc Pharmacol. 1986;8(Suppl 11): s122–7. doi: 10.1097/00005344-198511001-00022.
   PubMedGoogle Scholar
• Neutel JM, Smith DH, Ram CV, et al. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med. 1993;94(2):181–187. doi: 10.1016/0002-9343(93)90181-n.
   PubMed Web of Science ®Google Scholar
• Zhou WJ, Wang RY, Li Y, et al. A randomized controlled study on the effects of bisoprolol and atenolol on sympathetic nervous activity and Central aortic pressure in patients with essential hypertension. PLoS One. 2013;8(9):e72102. doi: 10.1371/journal.pone.0072102.
   PubMed Web of Science ®Google Scholar
• Czuriga I, Riecansky I, Bodnar J, et al. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther. 2003;17(3):257–263. doi: 10.1023/a:1026180325278.
   PubMed Web of Science ®Google Scholar
• Lechat P, Brunhuber K, Hofmann R, et al. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13.
   PubMed Web of Science ®Google Scholar
• Group M-HS. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in-congestive heart failure (MERIT-HF). The Lancet. 1999;353(9169):2001–2007.
   PubMed Web of Science ®Google Scholar
• Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–225. doi: 10.1093/eurheartj/ehi115.
   PubMed Web of Science ®Google Scholar
• Eichhorn EJ, Bristow MR. The carvedilol prospective randomized cumulative survival (COPERNICUS) trial. Curr Control Trials Cardiovasc Med. 2001;2(1):20–23. doi: 10.1186/cvm-2-1-020.
   PubMedGoogle Scholar
• Maddox TM, Januzzi JL, Jr., Allen LA, et al. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol. 2021;77(6):772–810. doi: 10.1016/j.jacc.2020.11.022.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (ESC). developed with the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975. doi: 10.1002/ejhf.592.
   PubMed Web of Science ®Google Scholar
• Simon T, Mary-Krause M, Funck-Brentano C, et al. Bisoprolol dose–response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). Eur Heart J. 2003;24(6):552–559. doi: 10.1016/s0195-668x(02)00743-1.
   PubMed Web of Science ®Google Scholar
• Toyoda S, Haruyama A, Inami S, et al. Protective effects of bisoprolol against myocardial injury and pulmonary dysfunction in patients with chronic heart failure. Int J Cardiol. 2017;226:71–76. doi: 10.1016/j.ijcard.2016.10.046.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396(10244):121–128. doi: 10.1016/S0140-6736(20)30748-0.
   PubMed Web of Science ®Google Scholar
• Liu RC. Focused treatment of heart failure with reduced ejection fraction using sacubitril/valsartan. Am J Cardiovasc Drugs. 2018;18(6):473–482. doi: 10.1007/s40256-018-0280-5.
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Ohtani T, Mizote I, et al. Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension. J Cardiol. 2013;61(6):417–422. doi: 10.1016/j.jjcc.2013.01.009.
   PubMed Web of Science ®Google Scholar
• Orso F, Baldasseroni S, Fabbri G, et al. Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian survey on acute heart failure. Eur J Heart Fail. 2009;11(1):77–84. doi: 10.1093/eurjhf/hfn008.
   PubMed Web of Science ®Google Scholar
• Böhm M, Link A, Cai D, et al. Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: data from the survival of patients with acute heart failure in need of intravenous inotropic support trial. Crit Care Med. 2011;39(5):940–944. doi: 10.1097/CCM.0b013e31820a91ed.
   PubMed Web of Science ®Google Scholar
• Prins KW, Neill JM, Tyler JO, et al. Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis. JACC Heart Fail. 2015;3(8):647–653. doi: 10.1016/j.jchf.2015.03.008.
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Chaudhuri D, Vedanthan R, et al. Early intravenous beta-blockers in patients with acute coronary syndrome–a meta-analysis of randomized trials. Int J Cardiol. 2013;168(2):915–921. doi: 10.1016/j.ijcard.2012.10.050.
   PubMed Web of Science ®Google Scholar
• Sterling LH, Filion KB, Atallah R, et al. Intravenous beta-blockers in ST-segment elevation myocardial infarction: a systematic review and meta-analysis. Int J Cardiol. 2017;228:295–302. doi: 10.1016/j.ijcard.2016.11.133.
   PubMed Web of Science ®Google Scholar
• García-Ruiz Jose M, Fernández-Jiménez R, García-Alvarez A, et al. Impact of the timing of metoprolol administration during STEMI on infarct size and ventricular function. J Am Coll Cardiol. 2016;67(18):2093–2104. doi: 10.1016/j.jacc.2016.02.050.
   PubMed Web of Science ®Google Scholar
• Podlesnikar T, Pizarro G, Fernández-Jiménez R, et al. Left ventricular functional recovery of infarcted and remote myocardium after ST-segment elevation myocardial infarction (METOCARD-CNIC randomized clinical trial substudy). J Cardiovasc Magn Reson. 2020;22(1):44. doi: 10.1186/s12968-020-00638-8.
   PubMed Web of Science ®Google Scholar
• Boudonas GE. β-Blockers in coronary artery disease management. Hippokratia. 2010;14(4):231–235.
   PubMed Web of Science ®Google Scholar
• Bugiardini R, Cenko E, Ricci B, et al. Comparison of early versus delayed oral β blockers in acute coronary syndromes and effect on outcomes. Am J Cardiol. 2016;117(5):760–767. doi: 10.1016/j.amjcard.2015.11.059.
   PubMed Web of Science ®Google Scholar
• de Matos Soeiro A, de Barros ESPG, Roque EA, et al. Mortality reduction with use of oral beta-blockers in patients with acute coronary syndrome. Clinics (Sao Paulo). 2016;71(11):635–638. doi: 10.6061/clinics/2016(11)03.
   PubMed Web of Science ®Google Scholar
• Maclean E, Zheng S, Nabeebaccus A, et al. Effect of early bisoprolol administration on ventricular arrhythmia and cardiac death in patients with non-ST elevation myocardial infarction. Heart Asia. 2015;7(2):46–51.
   PubMedGoogle Scholar
• Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(2):119–177. doi: 10.1093/eurheartj/ehx393.
   PubMed Web of Science ®Google Scholar
• Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal. 2021;42(14):1289–1367. doi: 10.1093/eurheartj/ehaa575.
   PubMed Web of Science ®Google Scholar
• Huang HL, Fox KA. The impact of beta-blockers on mortality in stable angina: a meta-analysis. Scott Med J. 2012;57(2):69–75. doi: 10.1258/smj.2011.011274.
   PubMed Web of Science ®Google Scholar
• Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391(10115):31–40. doi: 10.1016/S0140-6736(17)32714-9.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Steg G, Deedwania P, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. Jama. 2012;308(13):1340–1349. doi: 10.1001/jama.2012.12559.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Bhatt DL, Steg PG, et al. β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes. 2014;7(6):872–881. doi: 10.1161/CIRCOUTCOMES.114.001073.
   PubMed Web of Science ®Google Scholar
• National Guideline Centre (UK). Evidence review for beta-blockers: acute coronary syndromes: evidence review H. London: National Institute for Health and Care Excellence (NICE); 2020 Nov. (NICE Guideline, No. 185.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK565360/
   Google Scholar
• Sabidó M, Thilo H, Guido G. Long-term effectiveness of bisoprolol in patients with angina: a real-world evidence study. Pharmacol Res. 2019;139:106–112. doi: 10.1016/j.phrs.2018.10.031.
   PubMed Web of Science ®Google Scholar
• Wu VC, Chen SW, Ting PC, et al. Selection of β-blocker in patients with cirrhosis and acute myocardial infarction: a 13-Year nationwide population-based study in Asia. J Am Heart Assoc. 2018;7(19):e008982.
   PubMed Web of Science ®Google Scholar
• Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes: the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(3):407–477. doi: 10.1093/eurheartj/ehz425.
   PubMed Web of Science ®Google Scholar
• Mancia G, Kreutz R, Brunström M, et al. 2023 ESH guidelines for the management of arterial hypertension the Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023 Jun 21 [cited 2023; Jul 21]; Publish Ahead of Print. Available from: doi: 10.1097/HJH.0000000000003480.
   Google Scholar
• Grassi G, et al. Sympathetic overdrive in hypertension: clinical and therapeutic relevance. ESC Council Cardiol Pract. 2015;13:36–24.
   Google Scholar
• Shaman AM, Smyth B, Arnott C, et al. Comparative efficacy and safety of BP-Lowering pharmacotherapy in patients undergoing maintenance dialysis: a network Meta-Analysis of randomized, controlled trials. Clin J Am Soc Nephrol. 2020;15(8):1129–1138. doi: 10.2215/CJN.12201019.
   PubMed Web of Science ®Google Scholar
• Badve SV, Roberts MA, Hawley CM, et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58(11):1152–1161. doi: 10.1016/j.jacc.2011.04.041.
   PubMed Web of Science ®Google Scholar
• Kotecha D, Gill SK, Flather MD, et al. Impact of renal impairment on Beta-Blocker efficacy in patients with heart failure. J Am Coll Cardiol. 2019;74(23):2893–2904. doi: 10.1016/j.jacc.2019.09.059.
   PubMed Web of Science ®Google Scholar
• Molnar AO, Petrcich W, Weir MA, et al. The association of beta-blocker use with mortality in elderly patients with congestive heart failure and advanced chronic kidney disease. Nephrol Dial Transplant. 2020;35(5):782–789. doi: 10.1093/ndt/gfz167.
   PubMed Web of Science ®Google Scholar
• Fu EL, Uijl A, Dekker FW, et al. Association between β-Blocker use and mortality/morbidity in patients with heart failure with reduced, midrange, and preserved ejection fraction and advanced chronic kidney disease. Circ Heart Fail. 2020;13(11):e007180.
   PubMed Web of Science ®Google Scholar
• Jin J, Guo X, Yu Q. Effects of beta-blockers on cardiovascular events and mortality in dialysis patients: a systematic review and meta-analysis. Blood Purif. 2019;48(1):51–59. doi: 10.1159/000496083.
   PubMed Web of Science ®Google Scholar
• Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42(2):201–208. doi: 10.1016/s0735-1097(03)00572-2.
   PubMed Web of Science ®Google Scholar
• Weir MA, Dixon SN, Fleet JL, et al. β-Blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol. 2015;26(4):987–996. doi: 10.1681/ASN.2014040324.
   PubMed Web of Science ®Google Scholar
• Wu PH, Lin YT, Kuo MC, et al. β-blocker dialyzability and the risk of mortality and cardiovascular events in patients undergoing hemodialysis. Nephrol Dial Transplant. 2020;35(11):1959–1965. doi: 10.1093/ndt/gfaa058.
   PubMed Web of Science ®Google Scholar
• Assimon MM, Brookhart MA, Fine JP, et al. A comparative study of carvedilol versus metoprolol initiation and 1-year mortality among individuals receiving maintenance hemodialysis. Am J Kidney Dis. 2018;72(3):337–348. doi: 10.1053/j.ajkd.2018.02.350.
   PubMed Web of Science ®Google Scholar
• Tao S, Huang J, Xiao J, et al. Cardio-selective versus non-selective β-blockers for cardiovascular events and mortality in long-term dialysis patients: a systematic review and meta-analysis. PLoS One. 2022;17(12):e0279171. doi: 10.1371/journal.pone.0279171.
   PubMed Web of Science ®Google Scholar
• Wu P-H, Lin Y-T, Liu J-S, et al. Comparative effectiveness of bisoprolol and carvedilol among patients receiving maintenance hemodialysis. Clin Kidney J. 2021;14(3):983–990. doi: 10.1093/ckj/sfaa248.
   PubMed Web of Science ®Google Scholar
• Giannattasio C, Cattaneo BM, Seravalle G, et al. Alpha 1-blocking properties of carvedilol during acute and chronic administration. J Cardiovasc Pharmacol. 1992;19(Suppl 1): s18–22. doi: 10.1097/00005344-199219001-00005.
   PubMedGoogle Scholar
• Tamargo J, Delpón E. Optimization of beta-blockers’ pharmacology. J Cardiovasc Pharmacol. 1990;16(Suppl 5): s10–S18. doi: 10.1097/00005344-199006165-00003.
   PubMedGoogle Scholar
• Leitao Filho FS, Alotaibi NM, Yamasaki K, et al. The role of beta-blockers in the management of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2018;12(2):125–135. doi: 10.1080/17476348.2018.1419869.
   PubMed Web of Science ®Google Scholar
• Baker JG, Wilcox RG. β-blockers, heart disease and COPD: current controversies and uncertainties. Thorax. 2017;72(3):271–276. doi: 10.1136/thoraxjnl-2016-208412.
   PubMed Web of Science ®Google Scholar
• Gulea C, Zakeri R, Alderman V, et al. Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison. Respir Res. 2021;22(1):64. doi: 10.1186/s12931-021-01661-8.
   PubMed Web of Science ®Google Scholar
• Yang Y-L, Xiang Z-J, Yang J-H, et al. Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2020;41(46):4415–4422. doi: 10.1093/eurheartj/ehaa793.
   PubMed Web of Science ®Google Scholar
• Neef P, Burrell L, McDonald C, et al. Commencement of cardioselective bet-blockers during hospitalisation for acute exacerbations of chronic obstructive pulmonary disease. Intern Med J. 2017;47(9):1043–1050. doi: 10.1111/imj.13518.
   PubMed Web of Science ®Google Scholar
• Hawkins NM, MacDonald MR, Petrie MC, et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. European J of Heart Fail. 2009;11(7):684–690. doi: 10.1093/eurjhf/hfp066.
   PubMed Web of Science ®Google Scholar
• Foresi A, Cavigioli G, Signorelli G, et al. Is the use of β-blockers in COPD still an unresolved dilemma? Respiration. 2010;80(3):177–187. doi: 10.1159/000318583.
   PubMed Web of Science ®Google Scholar
• Zvizdic F, Begic E, Mujakovic A, et al. Beta-blocker use in moderate and severe chronic obstructive pulmonary disease. Med Arch. 2019;73(2):72–75. doi: 10.5455/medarh.2019.73.72-75.
   PubMedGoogle Scholar
• Bhatt SP, Wells JM, Kinney GL, et al. β-Blockers are associated with a reduction in COPD exacerbations. Thorax. 2016;71(1):8–14. doi: 10.1136/thoraxjnl-2015-207251.
   PubMed Web of Science ®Google Scholar
• Agostoni P, Contini M, Cattadori G, et al. Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? Eur J Heart Fail. 2007;9(8):827–833. doi: 10.1016/j.ejheart.2007.04.006.
   PubMed Web of Science ®Google Scholar
• Contini M, Apostolo A, Cattadori G, et al. Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial. Int J Cardiol. 2013;168(3):2134–2140. doi: 10.1016/j.ijcard.2013.01.277.
   PubMed Web of Science ®Google Scholar
• Puente-Maestu L, Álvarez-Sala LA, de Miguel-Díez J. Beta-blockers in patients with chronic obstructive disease and coexistent cardiac illnesses. COPD Res Pract. 2015;1(1):1–10. doi: 10.1186/s40749-015-0013-y.
   Google Scholar
• Salpeter SR, Ormiston TM, Salpeter EE, et al. Cardioselective beta‐blockers for reversible airway disease. Cochrane Database Syst Rev. 2002;(4):CD002992. doi: 10.1002/14651858.CD002992.
   Google Scholar
• Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta‐blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;2005(4):CD003566. doi: 10.1002/14651858.CD003566.pub2.
   PubMedGoogle Scholar
• Lainscak M, Podbregar M, Kovacic D, et al. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respir Med. 2011;105(Suppl 1):S44–S49. doi: 10.1016/S0954-6111(11)70010-5.
   PubMedGoogle Scholar
• Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55(17):1780–1787. doi: 10.1016/j.jacc.2010.01.024.
   PubMed Web of Science ®Google Scholar
• Statsenko M, Derevianchenko M, Chernikov M, et al. Efficacy and safety of bisoprololal in hypertensive patients with cardiovascular disease and chronic obstructive pulmonary disease. Kardiologiia. 2014;54(1):48–54. doi: 10.18565/cardio.2014.1.48-54.
   PubMed Web of Science ®Google Scholar
• Sessa M, Mascolo A, Mortensen RN, et al. Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta‐blocker use: a Danish nationwide cohort study. Eur J Heart Fail. 2018;20(3):548–556. doi: 10.1002/ejhf.1045.
   PubMed Web of Science ®Google Scholar
• Su VY-F, Chang Y-S, Hu Y-W, et al. Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease. Medicine (Baltimore). 2016;95(5):e2427. doi: 10.1097/MD.0000000000002427.
   PubMed Web of Science ®Google Scholar
• Liao K-M, Lin T-Y, Huang Y-B, et al. The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study. Int J Chron Obstruct Pulmon Dis. 2017;12:2573–2581. doi: 10.2147/COPD.S141694.
   PubMed Web of Science ®Google Scholar
• Kubota Y, Asai K, Furuse E, et al. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:515–523. doi: 10.2147/COPD.S79942.
   PubMed Web of Science ®Google Scholar
• Kukes VG, Ostroumova OD, Mamaev VI[, et al. Efficacy and safety of different beta-blockers in patients with isolated systolic hypertension associated with diabetes mellitus and obstructive pulmonary diseases. Ter Arkh. 2003;75(8):43–47.
   PubMed Web of Science ®Google Scholar
• Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16(6):e1-194–194.
   PubMed Web of Science ®Google Scholar
• Neef PA, McDonald CF, Burrell LM, et al. Beta-blockers are under-prescribed in patients with chronic obstructive pulmonary disease and co-morbid cardiac disease. Intern Med J. 2016;46(11):1336–1340. doi: 10.1111/imj.13240.
   PubMed Web of Science ®Google Scholar
• Pinner N, Oliver W, Veasey T, et al. Frequency of β-Blocker use following exacerbations of COPD in patients with compelling indication for use. South Med J. 2019;112(11):586–590. doi: 10.14423/SMJ.0000000000001038.
   PubMed Web of Science ®Google Scholar
• Lipworth B, Skinner D, Devereux G, et al. Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease. Heart. 2016;102(23):1909–1914. doi: 10.1136/heartjnl-2016-309458.
   PubMed Web of Science ®Google Scholar
• Chatterjee SS. The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. J Cardiovasc Pharmacol. 1986;8(Suppl 11):S74–S7. doi: 10.1097/00005344-198511001-00013.
   PubMedGoogle Scholar
• Huang K-Y, Tseng P-T, Wu Y-C, et al. Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials. Sci Rep. 2021;11(1):452. doi: 10.1038/s41598-020-79837-3.
   PubMed Web of Science ®Google Scholar
• Janka HU, Ziegler AG, Disselhoff G, et al. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol. 1986;8(Suppl 11):S96–S9. doi: 10.1097/00005344-198511001-00018.
   PubMedGoogle Scholar
• Giesecke HG, Buchner-Möll D. Three years of experience with bisoprolol in the treatment of mild to moderate hypertension. J Cardiovasc Pharmacol. 1990;16(Suppl 5):S175–S178. doi: 10.1097/00005344-199000165-00031.
   PubMedGoogle Scholar
• Tsujimoto T, Yamamoto-Honda R, Kajio H, et al. Effectiveness of prior use of beta-blockers for preventing adverse influences of severe hypoglycemia in patients with diabetes: an observational study. Medicine (Baltimore). 2015;94(39):e1629. doi: 10.1097/MD.0000000000001629.
   PubMed Web of Science ®Google Scholar
• Witte KK, Drozd M, Walker AMN, et al. Mortality reduction associated with β-Adrenoceptor inhibition in chronic heart failure is greater in patients with diabetes. Diabetes Care. 2018;41(1):136–142. doi: 10.2337/dc17-1406.
   PubMed Web of Science ®Google Scholar
• Rerkpattanapipat P, Stanek MS, Kotler MN. Sex and the heart: what is the role of the cardiologist? Eur Heart J. 2001;22(3):201–208. doi: 10.1053/euhj.1999.2010.
   PubMed Web of Science ®Google Scholar
• Erdmann E. Safety and tolerability of beta-blockers: prejudices and reality. Eur Heart J Suppl. 2009;11(Suppl A):A21–A25. doi: 10.1093/eurheartj/sup001.
   Web of Science ®Google Scholar
• Nurmamedova GS, Mustafaev II. Analysis of variability of cardiac rhythm and sexual function in men with arterial hypertension during therapy with biosporolol and nebivolol. Klin Med (Mosk). 2012;90(12):56–59.
   PubMedGoogle Scholar
• Broekman CP, Haensel SM, Van de Ven LL, et al. Bisoprolol and hypertension: effects on sexual functioning in men. J Sex Marital Ther. 1992;18(4):325–331. doi: 10.1080/00926239208412857.
   PubMed Web of Science ®Google Scholar
• Fumagalli C, Maurizi N, Marchionni N, et al. β-blockers: their new life from hypertension to cancer and migraine. Pharmacol Res. 2020;151:104587. doi: 10.1016/j.phrs.2019.104587.
   PubMed Web of Science ®Google Scholar
• Lertvipapath P, Warunyuwong W. Beta-blocker and its neuropsychiatric effects. Thai J Pharm Sci. 2020;44(2):117–123.
   Google Scholar
• Cojocariu SA, Maștaleru A, Sascău RA, et al. Neuropsychiatric consequences of lipophilic beta-blockers. Medicina (Kaunas). 2021;57(2):155. doi: 10.3390/medicina57020155.
   PubMed Web of Science ®Google Scholar
• Ågesen FN, Weeke PE, Tfelt-Hansen P, et al. Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology. Pharmacol Res Perspect. 2019;7(4):e00496-e. doi: 10.1002/prp2.496.
   Web of Science ®Google Scholar
• Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients follwing 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J. 1987;8(suppl M):103–113. doi: 10.1093/eurheartj/8.suppl_m.103.
   PubMedGoogle Scholar
• Maack C, Tyroller S, Schnabel P, et al. Characterization of beta(1)-selectivity, adrenoceptor-G(s)-protein interaction and inverse agonism of nebivolol in human myocardium. Br J Pharmacol. 2001;132(8):1817–1826. doi: 10.1038/sj.bjp.0703992.
   PubMed Web of Science ®Google Scholar
• Bundkirchen A, Brixius K, Bölck B, et al. Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies. Eur J Pharmacol. 2003;460(1):19–26. doi: 10.1016/s0014-2999(02)02875-3.
   PubMed Web of Science ®Google Scholar
• Brixius K, Bundkirchen A, Bölck B, et al. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol. 2001;133(8):1330–1338. doi: 10.1038/sj.bjp.0704188.
   PubMed Web of Science ®Google Scholar
• AlHabeeb W, Mrabeti S, Abdelsalam AAI. Therapeutic properties of highly selective β-blockers with or without additional vasodilator properties: focus on bisoprolol and nebivolol in patients with cardiovascular disease. Cardiovasc Drugs Ther. 2021;36(5):959–971. doi: 10.1007/s10557-021-07205-y.
   PubMed Web of Science ®Google Scholar
• Yang T, Jiang Y, Hao Y, et al. Comparison of bisoprolol to a metoprolol CR/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study. Hypertens Res. 2017;40(1):79–86. doi: 10.1038/hr.2016.101.
   PubMed Web of Science ®Google Scholar
• Stoschitzky K, Stoschitzky G, Brussee H, et al. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology. 2006;106(4):199–206. doi: 10.1159/000093060.
   PubMed Web of Science ®Google Scholar